Skip to main content
. 2019 Jul 10;8(7):1011. doi: 10.3390/jcm8071011

Figure 1.

Figure 1

Clinical outcome estimated through the Kaplan-Meier analysis according to CTCs and cfDNA. Patients were categorized into two groups by means of the respective median baseline values. (Left): median survival times were 8.8 and 6.2 months for patients with ≤2 and >2 CTCs/3 mL of blood, respectively (p = 0.05). (Right): median survival times were 9.4 and 5.1 months for patients with ≤836.5 and >836.5 ng cfDNA/3 mL of plasma, respectively (p = 0.04).